Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIV · Real-Time Price · USD
32.41
+4.20 (14.89%)
May 20, 2026, 4:00 PM EDT - Market closed
Roivant Sciences Revenue
In the fiscal year ending March 31, 2026, Roivant Sciences had annual revenue of $8.26M, down -71.57%.
Revenue (ttm)
$5.74M
Revenue Growth
-80.24%
P/S Ratio
2,808.22
Revenue / Employee
$11,013
Employees
750
Market Cap
23.20B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 8.26M | -20.79M | -71.57% |
| Mar 31, 2025 | 29.05M | -3.66M | -11.19% |
| Mar 31, 2024 | 32.71M | -28.57M | -46.62% |
| Mar 31, 2023 | 61.28M | 5.99M | 10.84% |
| Mar 31, 2022 | 55.29M | 31.49M | 132.34% |
| Mar 31, 2021 | 23.80M | -43.89M | -64.85% |
| Mar 31, 2020 | 67.69M | 65.37M | 2,812.61% |
| Mar 31, 2019 | 2.32M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 5.70B |
| Incyte | 5.36B |
| Jazz Pharmaceuticals | 4.44B |
| Genmab | 3.90B |
| BioNTech SE | 3.23B |
| Royalty Pharma | 2.44B |
| Moderna | 2.23B |
| Ascendis Pharma | 998.25M |
ROIV News
- 16 hours ago - Roivant Sciences rises 15.2% - TheFly
- 16 hours ago - 2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug - Barrons
- 17 hours ago - Roivant Sciences rises 11.7% - TheFly
- 18 hours ago - Roivant Sciences Q4 Earnings Call Highlights - MarketBeat
- 20 hours ago - Roivant Sciences Earnings Call Transcript: Q4 2026 - Transcripts
- 20 hours ago - Roivant Sciences Earnings release: Q4 2026 - Filings
- 20 hours ago - Roivant Sciences Annual report: Q4 2026 - Filings
- 20 hours ago - Roivant Sciences Slides: Q4 2026 - Filings